LISEN lmprinting Diagnostics

WHAT WE DO

LisenID is advancing cancer healthcare, from screening and diagnostics to guided treatment, using epigenetic imprinting solutions. Through patent pending technology, LisenID is able to accurately and affordably detect over 12 types of cancers at the earliest stages. The methodology has been published in the Journal of Clinical Oncology and Clinical Epigenetics. All research have been validated through 8500+ clinical cases in partnership with multiple hospitals and medical centers in China and the US.

Learn More

PRECISION EPIGENETICS

Our novel epigenetic imprinting platform uses precision biomarkers for early cancer detection. We have 8500+ clinical cases that evidence best-in-class sensitivity and specificity across 12 cancer types.

Learn More

WHERE WE ARE

Our US lab is located at the Delaware Innovations Space, a state-of-the-art bioscience facility.

OUR PRODUCTS

Each cancer diagnostics kit provides precision detection with the highest sensitivity and specificity on the market.

Learn More

MERCK ACCELERATOR

Selected as the Best Partner among the Merck 2019 20 China Accelerator Top 6 Healthcare Startups, and awarded the Most Innovative Spirit Award.
TOP FINALISTS

Selected as a Top Finalists in the prestigious Global Top 100 Science Innovation Competition.
SCIENTIFIC INNOVATION

Awarded the 2019 Annual Scientific and Technological Innovation Award from Plug and Play China.
PATENTED TECHNOLOGY

9 int'l patents at national phase into US,6 into Europe, and 5 into Japan. 2 new patents into China applied and 8 new int'l patents applied.